Interferon lambda 4 genotype and pathway in alcoholic hepatitis

References

• Atkinson SR, Way MJ, McQuillin A, et al. Homozygosity for rs738409:G in PNPLA3 is associated with increased mortality following an episode of severe alcoholic hepatitis. J Hepatol. 2017;67(1):120–127.
   PubMed Web of Science ®Google Scholar
• Chamorro AJ, Torres JL, Miron-Canelo JA, et al. Systematic review with meta-analysis: the I148M variant of patatin-like phospholipase domain-containing 3 gene (PNPLA3) is significantly associated with alcoholic liver cirrhosis. Aliment Pharmacol Ther. 2014;40(6):571–581.
   PubMed Web of Science ®Google Scholar
• Buch S, Stickel F, Trepo E, et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet. 2015;47(12):1443–1448.
   PubMed Web of Science ®Google Scholar
• Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461–1465.
   PubMed Web of Science ®Google Scholar
• Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461(7262):399–401.
   PubMed Web of Science ®Google Scholar
• Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461(7265):798–801.
   PubMed Web of Science ®Google Scholar
• Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41(10):1100–1104.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41(10):1105–1109.
   PubMed Web of Science ®Google Scholar
• Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138(4):1338–1345.
   PubMed Web of Science ®Google Scholar
• Prokunina-Olsson L, Muchmore B, Tang W, et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat Genet. 2013;45(2):164–171.
   PubMed Web of Science ®Google Scholar
• Terczyńska-Dyla E, Bibert S, Duong FHT, et al. Reduced IFN lambda 4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. Nat Commun. 2014;5:5699.
   PubMed Web of Science ®Google Scholar
• Petta S, Valenti L, Tuttolomondo A, et al. Interferon lambda 4 rs368234815 TT > deltaG variant is associated with liver damage in patients with nonalcoholic fatty liver disease. Hepatology. 2017;66(6):1885–1893.
   PubMed Web of Science ®Google Scholar
• Eslam M, Hashem AM, Leung R, et al. Interferon-lambda rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat Commun. 2015;6(1):6422.
   PubMedGoogle Scholar
• Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4(1):69–77.
   PubMed Web of Science ®Google Scholar
• Ding SY, Khoury-Hanold W, Iwasaki A, et al. Epigenetic reprogramming of the type III interferon response potentiates antiviral activity and suppresses tumor growth. PLoS Biol. 2014;12(1):e1001758.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Hamming OJ, Ank N, et al. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol. 2007;81(14):7749–7758.
   PubMed Web of Science ®Google Scholar
• Pott J, Mahlakoiv T, Mordstein M, et al. IFN-lambda determines the intestinal epithelial antiviral host defense. Proc Natl Acad Sci USA. 2011;108(19):7944–7949.
   PubMed Web of Science ®Google Scholar
• Broggi A, Tan Y, Granucci F, et al. IFN-lambda suppresses intestinal inflammation by non-translational regulation of neutrophil function. Nat Immunol. 2017;18(10):1084–1093.
   PubMed Web of Science ®Google Scholar
• Chiriac MT, Buchen B, Wandersee A, et al. Activation of epithelial signal transducer and activator of transcription 1 by interleukin 28 controls mucosal healing in mice with colitis and is increased in mucosa of patients with inflammatory bowel disease. Gastroenterology. 2017;153(1):123–138.
   PubMed Web of Science ®Google Scholar
• Stoy S, Sandahl TD, Dige AK, et al. Highest frequencies of interleukin-22-producing T helper cells in alcoholic hepatitis patients with a favourable short-term course. PLoS One. 2013;8(1):e55101.
   PubMed Web of Science ®Google Scholar
• Espinosa V, Dutta O, McElrath C, et al. Type III interferon is a critical regulator of innate antifungal immunity. Sci Immunol. 2017;2(16):eaan5357.
   PubMed Web of Science ®Google Scholar
• Kelly A, Robinson MW, Roche G, et al. Immune cell profiling of IFN-λ response shows pDCs express highest level of IFN-λR1 and are directly responsive via the JAK-STAT pathway. J Interferon Cytokine Res. 2016;36(12):671–680.
   PubMed Web of Science ®Google Scholar
• Su QJ, Wang X, Zhou RH, et al. IFN-λ4 inhibits HIV infection of macrophages through signalling of IFN-λR1/IL-10R2 receptor complex. Scand J Immunol. 2018;88(5):e12717.
   PubMed Web of Science ®Google Scholar
• Liu BS, Janssen HL, Boonstra A. IL-29 and IFNα differ in their ability to modulate IL-12 production by TLR-activated human macrophages and exhibit differential regulation of the IFNγ receptor expression. Blood. 2011;117(8):2385–2395.
   PubMed Web of Science ®Google Scholar
• Ye L, Schnepf D, Becker J, et al. Interferon-λ enhances adaptive mucosal immunity by boosting release of thymic stromal lymphopoietin. Nat Immunol. 2019;20(5):593–601.
   PubMed Web of Science ®Google Scholar
• Dill MT, Duong FH, Vogt JE, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology. 2011;140(3):1021–1031.
   PubMed Web of Science ®Google Scholar
• Eriksen PL, Vilstrup H, Rigbolt K, et al. Non-alcoholic fatty liver disease alters expression of genes governing hepatic nitrogen conversion. Liver Int. 2019;39(11):2094–2101.
   PubMed Web of Science ®Google Scholar
• Chen JY, Wang CM, Chen TD, et al. Interferon-λ3/4 genetic variants and interferon-λ3 serum levels are biomarkers of lupus nephritis and disease activity in Taiwanese. Arthritis Res Ther. 2018;20(1):193.
   PubMedGoogle Scholar
• Egli A, Mandal J, Schumann DM, et al. IFN Lambda 3/4 locus polymorphisms and IFN Lambda 3 circulating levels are associated with COPD severity and outcomes. BMC Pulm Med. 2018;18(1):51.
   PubMedGoogle Scholar
• Sandahl TD, Gronbaek H, Moller HJ, et al. Hepatic macrophage activation and the LPS pathway in patients with alcoholic hepatitis: a prospective cohort study. Am J Gastroenterol. 2014;109(11):1749–1756.
   PubMed Web of Science ®Google Scholar
• Vergis N, Khamri W, Beale K, et al. Defective monocyte oxidative burst predicts infection in alcoholic hepatitis and is associated with reduced expression of NADPH oxidase. Gut. 2017;66(3):519–529.
   PubMed Web of Science ®Google Scholar
• Shasthry SM, Sharma MK, Shasthry V, et al. Efficacy of granulocyte colony-stimulating factor in the management of steroid-nonresponsive severe alcoholic hepatitis: a double-blind randomized controlled trial. Hepatology. 2019;70(3):802–811.
   PubMed Web of Science ®Google Scholar
• Obajemu AA, Rao N, Dilley KA, et al. IFN-lambda4 attenuates antiviral responses by enhancing negative regulation of IFN signaling. J Immunol. 2017;199(11):3808–3820.
   PubMed Web of Science ®Google Scholar
• Hong MA, Schwerk J, Lim C, et al. Interferon lambda 4 expression is suppressed by the host during viral infection. J Exp Med. 2016;213(12):2539–2552.
   PubMed Web of Science ®Google Scholar
• Duong FHT, Trincucci G, Boldanova T, et al. IFN-λ receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-λ3 genotype and with nonresponsiveness to IFN-α therapies. J Exp Med. 2014;211(5):857–868.
   PubMed Web of Science ®Google Scholar
• Ran M, Huang J, Liang H, et al. Alcohol attenuates anti-HCV function of IFN-lambda1 through up-regulation of PLASy expression in human hepatic cells. J Med Virol. 2018;90(6):1112–1120.
   PubMed Web of Science ®Google Scholar